key: cord-0765760-a4lacw1v authors: Kiser, Adam S.; Cooper, Gena L.; Napier, Jonathan D.; Howington, Gavin T. title: Color vision disturbances secondary to oral tranexamic acid date: 2021-05-29 journal: J Am Coll Emerg Physicians Open DOI: 10.1002/emp2.12456 sha: a3977685e77229b7ba17a9474d35d8f44ee676e9 doc_id: 765760 cord_uid: a4lacw1v Tranexamic acid (TXA) is an antifibrinolytic commonly used to reduce blood loss due to surgical procedures, heavy menstruation, trauma, bleeding disorders, among other uses. Possible adverse reactions associated with TXA include abdominal pain, headache, fatigue, cerebral thrombosis, dizziness, retinal artery occlusion, chromatopsia, and more. We present a case of acute color vision disturbance developed soon after initiation of oral TXA for epistaxis prophylaxis in the setting of factor VII deficiency. To our knowledge we report the only case of color vision disturbance in a pediatric patient and the only case after receiving oral TXA. Soon after discontinuing oral TXA the patient's altered perception of color vision resolved. The patient was subsequently discharged home with a prescription for an alternative antifibrinolytic (aminocaproic acid) and follow‐up with neuro‐ophthalmology. Tranexamic acid (TXA) is an antifibrinolytic medication that competitively inhibits the activation of plasminogen to plasmin. As a synthetic lysine analog, TXA adheres to the lysine binding sites on plasminogen and subsequently blocks the breakdown of fibrin clots by plasmin. 1 At high concentrations, TXA also directly inhibits the activity of plasmin. 2 TXA is commonly used to reduce perioperative blood loss during various surgical procedures (eg, coronary artery bypass grafting and aortic valve replacement) and has been shown to decrease transfusion requirements when used during surgical procedures. 3 Additionally, TXA is often used to decrease blood loss during trauma, heavy menstrual bleeding, hyphema, and various bleeding disorders (eg, factor VII deficiency). 3 TXA is available as an intravenous and oral formu-Supervising Editor: Mike Wells, MBBCh, PhD This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. © 2021 The Authors. JACEP Open published by Wiley Periodicals LLC on behalf of American College of Emergency Physicians lation and can be delivered via a variety of routes (eg, nebulized, oral, intravenous, and topical). One subset of patients that TXA often is used in is those with factor VII deficiency. Factor VII is a coagulation factor integral for adequate clot formation. Therefore, a deficiency often leads to a greater propensity to bleed. 4 In this patient population, TXA is used to mitigate bleeding episodes, most commonly being used for menorrhagia. 4, 5 Although serious adverse reactions to TXA are uncommon, several incidents of ophthalmologic aberrations have been reported in the literature. Package inserts for both the intravenous and oral formulations include warnings for visual and ocular effects, and acquired defective color vision is listed as a contraindication for the use of intravenous TXA. 6, 7 We present a novel case of color vision disturbance without identifiable ocular pathology in a pediatric patient with factor VII deficiency following treatment with oral TXA for prevention of further epistaxis. A 7-year-old female presented to the emergency department (ED) for evaluation of acute onset altered color perception. The patient reported changes in her color vision (chromatopsia), specifically noting that objects appeared oddly colored. She mentions that her mother was transitioning from purple to white and vice versa. Based on how the patient describes the altered color perception it seems both eyes were affected. However, she was not distressed regarding the current events but more surprised and confused. Past medical history included factor VII deficiency, portal hypertension with esophageal varices, aortic stenosis with hyperplasia of the aortic arch, hypertension, sickle cell trait, and a splenorenal shunt. The patient's mother reached out to her hematologist regarding the constellation of ophthalmologic symptoms. She was instructed to take the patient to the ED for further evaluation. At that time, the mother had already discontinued TXA. The patient was evaluated in the same ED 3 days before owing to an episode of epistaxis that developed spontaneously. During this visit she was hemodynamically stable with no fever, well appearing, and the nosebleed had resolved before arriving in the ED. The Ophthalmology reported to the ED and note that the patient's eyes were normal with healthy-appearing optic nerves, no relative afferent pupillary defect, and no pertinent findings on the dilated fundus exam. There was no evidence of a focal neurological symptom upon examination, so further imaging was not ordered. Ophthalmology could provide no potential etiology for the color vision disturbances and the patient's hematologist recommended no further testing. Hematology recommended permanent discontinuation of TXA and cleared the patient to begin taking aminocaproic acid, an alternative antifibrinolytic agent, and to follow up with the patient's hematologist. Ophthalmology instructed the patient's mother to keep a symptom journal and to follow up with neuro-ophthalmology in 3 to 4 weeks. Currently, the patient has not followed up because of the COVID-19 pandemic but does plan to follow up in the near future. The ED pharmacist followed up with the patient's mother 4 months after the second ED visit. The mother notes no additional issues with color vision disturbances since stopping TXA and starting aminocaproic acid. We have reported a case of transient color vision disturbance in a pediatric patient after taking oral TXA for prevention of epistaxis, which has not been previously reported in the medical literature. In To our knowledge this is the first case of color vision disturbance in a pediatric patient treated with oral tranexamic acid. Current literature supports the assertation that TXA has the potential to cause ophthalmologic adverse effects with the intravenous and oral formulations. However, our case is unique in that the patient developed ocular manifestations secondary to the oral formulation of TXA and the patient is pediatric. Further investigation is needed to better elucidate why TXA may cause color vision disturbances. At this time physician and nonphysician healthcare practitioners should be aware of this uncommon but possible adverse event. All authors contributed equally to this work. Tranexamic acid: a clinical review The current place of tranexamic acid in the management of bleeding Tranexamic acid: a review of its use in the treatment of hyperfibrinolysis Factor VII deficiency: from basics to clinical laboratory diagnosis and patient management Factor VII deficiency: clinical phenotype, genotype and therapy Tranexamic Acid Injection IL: Baxter Healthcare Corporation Tranexamic Acid Tablet Retinal artery occlusion associated with tranexamic acid therapy Central venous stasis retinopathy following the use of tranexamic acid Tranexamic acid-induced visual impairment in a hemodialysis patient Antifibrinolytic therapy use to mitigate blood loss during staged complex major spine surgery: postoperative visual color changes after tranexamic acid administration Color vision disturbances secondary to oral tranexamic acid The authors declare no conflict of interest.